You are a **world-class hedge-fund quant developer / PM / CRO** — someone who has built, sized,
and *killed* real systematic books with real money, sat on investment + risk committees, and
signed off (or refused to) on capital allocations. I'm the solo operator of a systematic trading
platform ("MrTrader"). You reviewed this program ~6 weeks ago and your panel's verdict was
**"we have alternative risk premia, not alpha; it's effectively a single bet; carry is unproven;
the app is ahead of the alpha."** We took that seriously and **executed almost all of it** (see
file 02). I want another **brutally honest** read — candor over comfort. If we're about to size a
multiple-testing artifact, fool ourselves on diversification, or deploy a fragile book, **say so
plainly and tell me how to prove it.**

I've attached 7 files. Please read them before answering:
- **01_PROGRAM_OVERVIEW** — what it is, what's live
- **02_WHAT_WE_DID_SINCE_LAST_PANEL** — your v10 advice → what we executed + found (the scorecard)
- **03_THE_FOUR_PREMIA** — the 4 paper risk premia (trend live; carry; xs-momentum; VIX-VRP) + numbers + correlations
- **04_VALIDATION_AND_MULTIPLE_TESTING** — our gate, its proven Type-I/II behavior, and the uncounted family-wise testing burden
- **05_GO_LIVE_DECISIONS** — sizing, two-venue risk, the paper→capital promotion ladder (all UNbuilt)
- **06_DIVERSIFICATION_AND_TAILS** — do the 4 premia actually co-crash? (what we have + the gaps)
- **07_THE_QUESTIONS** — the precise asks

## Context in one breath
After 2 years of pre-registered search, we trade ONE edge live with conviction: **multi-asset
ETF trend (Sharpe ~0.72; vindicated post-2015 at +0.77).** On newly-bought survivorship-free
**futures** data we then mined a real second engine: **carry + cross-sectional momentum**, which
as an equal-weight book improves the live book with **residual-α t = 2.29**. We also reversed a
wrongly-parked **VIX-curve VRP** (Sharpe 0.64, survives Feb-2018 + COVID via a gate). The free
factor zoo is now **exhausted** (6 factors tested, only xs-momentum survived). **IBKR futures
execution is days away.** So we are at the inflection from *research* to *real capital* — and the
layer that decides sizing, cross-venue risk, and promotion **does not exist yet.**

## What I want from you — specific, prioritized, implementable. Three themes:

**A — GO-LIVE: capital sizing & risk architecture (the layer we never built).**
We have 4 paper premia (trend LIVE on Alpaca equities; carry/xsmom/VRP to run on IBKR futures).
How do we size each sleeve AND the whole book — by drawdown / vol-target / margin, NOT Kelly?
How do we run ONE coherent book across **two brokers** (Alpaca equities + IBKR futures) with
different margin/execution — risk aggregation, a single kill-switch, a realized-correlation-spike
de-gross trigger? What is the right **promotion ladder** (paper → tiny-live → scale), and the
exact evidence threshold at each rung? **What would make you NOT deploy?**

**B — IS THE EDGE REAL, OR MULTIPLE-TESTING RESIDUE? (the most important honesty check.)**
We've tried **~20 sleeve families** over 2 years. Our gate treats "rules-based sleeves as
OOS-by-construction" — but that's false at the *family-selection* level, and we have NOT yet
counted the family-wise burden (your panel's sharpest prior point; still undone). Does our
surviving book (carry/xsmom/VRP; the t=2.29 result) survive an honest family-wise / deflated-
significance correction? How exactly would you build a **null-strategy zoo** to calibrate our
per-family false-positive rate, and what deflated bar should the survivors clear? Be concrete
enough that I can build it.

**C — DO THE FOUR PREMIA ACTUALLY DIVERSIFY, OR CO-CRASH? (the "single bet" critique, revisited.)**
Pairwise correlations are low (carry/xsmom/VRP-to-trend ≈ 0.25 / 0.12 / 0.46), but low average
correlation ≠ low *tail* correlation. Trend, carry, xs-mom, and short-vol could all be "risk-on"
premia that blow up together; our CPCV has **no clean crisis fold.** Are we genuinely diversified
or kidding ourselves? How do you stress-test a book whose backtest never saw an isolated crisis
fold? Is there a deliberately **convex / defensive** sleeve we're missing that we could build from
the data we own (survivorship-free futures incl. full term structure + VIX curve + macro)?

Where you make a claim, say what evidence would confirm or refute it — I have the data and the
harness to re-run almost anything. If you think we already got something wrong (a kept sleeve that
shouldn't be, a sizing instinct that's dangerous, a "diversifier" that isn't), lead with that.
Thank you — be the skeptic on my risk committee.
